XML 16 R26.htm IDEA: XBRL DOCUMENT
v3.19.3

Research Collaboration and Sub-licensing Agreements (Details) € in Thousands |  |  |  | 3 Months Ended | 9 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
May 07, 2019 protein antibody_and_vaccine | May 05, 2019 | Jun. 30, 2017 EUR (€) | Jun. 30, 2017 USD ($) | Sep. 30, 2019 USD ($) collaboration_project | Sep. 30, 2018 USD ($) | Sep. 30, 2019 USD ($) collaboration_project | Sep. 30, 2018 USD ($) | Apr. 26, 2019 | Dec. 31, 2018 USD ($) | Jun. 30, 2017 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Duration of agreement |  |  | 2 years | 2 years |  |  |  |  |  |  |
Payment for research and development agreement |  |  | € 1,000 | $ 1,100,000 |  |  |  |  |  |  |
Prepaid research and development |  |  |  |  | $ 0 |  | $ 0 |  |  | $ 300,000 |
Research and development - related party |  |  |  |  | 101,849 | $ 288,175 | 827,632 | $ 1,021,573 |  |  |
Alphazyme |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity percentage |  | 7.50% |  |  |  |  |  |  |  |  |
Ownership interest consideration receivable upon extension of exclusivity period |  | 2.50% |  |  |  |  |  |  |  |  |
Novovet |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity percentage |  |  |  |  |  |  |  |  | 20.00% |  |
Collaborative Arrangement | Alphazyme |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Exclusivity period |  | 18 months |  |  |  |  |  |  |  |  |
Option to extend exclusivity period |  | 12 months |  |  |  |  |  |  |  |  |
Collaborative Arrangement | Serum |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine | 12 |  |  |  |  |  |  |  |  |  |
Option to obtain exclusive commercial sub-license for number of proteins | protein | 12 |  |  |  |  |  |  |  |  |  |
Research funding, milestone payments and royalties, period | 15 years |  |  |  |  |  |  |  |  |  |
Revenue from collaborative arrangement, recognized |  |  |  |  | 13,000 |  | 13,000 |  |  |  |
Revenue from collaborative arrangement, contract liability |  |  |  |  | $ 70,000 |  | $ 70,000 |  |  |  |
RSA |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment for research and development agreement | € |  |  | 1,000 |  |  |  |  |  |  |  |
Payment for additional development and commercialization | € |  |  | € 1,500 |  |  |  |  |  |  |  |
RSA | Minimum |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenue sharing, percentage |  |  | 50.00% | 50.00% |  |  |  |  |  |  |
RSA | Maximum |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenue sharing, percentage |  |  | 75.00% | 75.00% |  |  |  |  |  |  |
RSA | BDI Holdings |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity interest acquired |  |  | 16.10% | 16.10% |  |  |  |  |  |  |
RSA | VLPbio |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Equity interest acquired |  |  | 3.30% | 3.30% |  |  |  |  |  |  |
RSA | BDI |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Duration of agreement |  |  | 2 years | 2 years |  |  |  |  |  |  |
Obligation for payment for research and development, minimum | € |  |  | € 936 |  |  |  |  |  |  |  |
Obligation for payment for research and development, maximum | € |  |  | € 8,000 |  |  |  |  |  |  |  |
RSA | BDI | Minimum |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenue sharing, percentage |  |  | 50.00% | 50.00% |  |  |  |  |  |  |
RSA | BDI | Maximum |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenue sharing, percentage |  |  | 75.00% | 75.00% |  |  |  |  |  |  |
SFA |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |
Duration of agreement |  |  | 2 years | 2 years |  |  |  |  |  |  |
Obligation for payment for research and development, minimum |  |  |  |  |  |  |  |  |  |  | $ 1,000,000
Number of collaboration project, completed | collaboration_project |  |  |  |  | 4 |  | 4 |  |  |  |
Outstanding commitment |  |  |  |  |  |  |  |  |  |  | $ 1,000,000
Number of collaboration project, in progress | collaboration_project |  |  |  |  | 3 |  | 3 |  |  |  |

X
- Definition Collaborative Arrangement, Duration Of Agreement + References No definition available. + Details
Name: | dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Equity Interest Acquired + References No definition available. + Details
Name: | dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Exclusivity Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementExclusivityPeriod
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Maximum Obligation For Research And Development + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Minimum Obligation For Research And Development + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization + References No definition available. + Details
Name: | dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Number of Collaboration Project, Completed + References No definition available. + Details
Name: | dyai_CollaborativeArrangementNumberofCollaborationProjectCompleted
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Number of Collaboration Project, In Progress + References No definition available. + Details
Name: | dyai_CollaborativeArrangementNumberofCollaborationProjectInProgress
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Option To Extend Exclusivity Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Outstanding Commitment + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOutstandingCommitment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Payment for Additional Development and Commercialization + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentforAdditionalDevelopmentandCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Payment for Research and Development Agreement + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentforResearchandDevelopmentAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period + References No definition available. + Details
Name: | dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Revenue Sharing, Percentage + References No definition available. + Details
Name: | dyai_CollaborativeArrangementRevenueSharingPercentage
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Prepaid Research and Development + References No definition available. + Details
Name: | dyai_PrepaidResearchandDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research and Development Expense, Related Party + References No definition available. + Details
Name: | dyai_ResearchandDevelopmentExpenseRelatedParty
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue from Collaborative Arrangement, Contract Liability + References No definition available. + Details
Name: | dyai_RevenueFromCollaborativeArrangementContractLiability
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from Collaborative Arrangement, Recognized + References No definition available. + Details
Name: | dyai_RevenueFromCollaborativeArrangementRecognized
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_SerumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_VLPbioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ServiceFrameworkAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |